The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

Abstract Hypoxia‐inducible factor 1 (HIF‐1) plays an indispensable role in the hypoxic tumor
microenvironment. Hypoxia and HIF‐1 are involved in multiple aspects of tumor progression …

Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

Tumor immunotherapy has transformed neoplastic disease management, yet low response
rates and immune complications persist as major challenges. Extracellular vesicles …

Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer
advantages including ease of dosing, ability to manage immune-related adverse events …

Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to
mediate the mechanism of immune tolerance and provide immune homeostasis …

Background The systemic immune-inflammation index (SII) is a novel biomarker to predict
the prognosis of some malignant tumors based on neutrophil, platelet, and lymphocyte …

Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains
dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint …

We developed a custom-designed liposome carrier for codelivery of a potent immunogenic
cell death (ICD) stimulus plus an inhibitor of the indoleamine 2, 3-dioxygenase (IDO-1) …

Immunotherapy has achieved great success recently and opened a new avenue for anti-
tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) …